-$0.30 Earnings Per Share Expected for AC Immune SA (NASDAQ:ACIU) This Quarter

Wall Street brokerages predict that AC Immune SA (NASDAQ:ACIU) will announce earnings per share of ($0.30) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AC Immune’s earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.33). AC Immune reported earnings per share of ($0.28) during the same quarter last year, which suggests a negative year over year growth rate of 7.1%. The firm is scheduled to issue its next earnings report on Friday, November 12th.

On average, analysts expect that AC Immune will report full year earnings of ($0.72) per share for the current year, with EPS estimates ranging from ($1.20) to $0.11. For the next financial year, analysts forecast that the business will report earnings of ($0.25) per share, with EPS estimates ranging from ($1.07) to $0.22. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for AC Immune.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, August 3rd. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). AC Immune had a negative net margin of 405.01% and a negative return on equity of 35.48%.

A number of equities analysts have recently issued reports on ACIU shares. SVB Leerink reissued a “buy” rating and set a $17.00 price objective on shares of AC Immune in a research report on Sunday, August 8th. Zacks Investment Research upgraded AC Immune from a “sell” rating to a “hold” rating in a report on Monday.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BVF Inc. IL raised its stake in shares of AC Immune by 13.9% in the second quarter. BVF Inc. IL now owns 8,545,179 shares of the company’s stock valued at $67,763,000 after buying an additional 1,040,600 shares during the period. EcoR1 Capital LLC raised its stake in shares of AC Immune by 51.4% during the 1st quarter. EcoR1 Capital LLC now owns 3,648,163 shares of the company’s stock valued at $27,763,000 after purchasing an additional 1,237,923 shares during the period. Point72 Asset Management L.P. purchased a new stake in AC Immune during the 2nd quarter worth about $2,986,000. Wells Fargo & Company MN boosted its stake in AC Immune by 4.4% in the 2nd quarter. Wells Fargo & Company MN now owns 335,104 shares of the company’s stock worth $2,658,000 after purchasing an additional 14,175 shares during the period. Finally, Morgan Stanley grew its holdings in AC Immune by 223.6% during the 2nd quarter. Morgan Stanley now owns 267,935 shares of the company’s stock valued at $2,124,000 after buying an additional 185,128 shares in the last quarter. Institutional investors and hedge funds own 25.04% of the company’s stock.

Shares of ACIU traded down $0.27 during trading hours on Monday, hitting $6.72. 378,223 shares of the stock were exchanged, compared to its average volume of 1,189,497. The business has a 50-day moving average of $7.11 and a 200-day moving average of $7.15. AC Immune has a fifty-two week low of $4.42 and a fifty-two week high of $12.61. The firm has a market capitalization of $488.23 million, a P/E ratio of -6.00 and a beta of 0.79.

About AC Immune

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

Further Reading: How does the Beige Book influence monetary policy?

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.